bluuebunny/crossref_metadata_2025_split huggingface dataset:
Integrating analysis of circular RNA and mRNA expression profiles in doxorubicin induced cardiotoxicity mice
Authors: Xing Xiaoqing , Tan Zhenzhen , Zhi Xuran , Sun Heming , Yang Jing , Li Longfei , Liu Yi , Wang Lei , Dong Zhanjun , Guo Huicai 
Published: October 2021

AbstractDoxorubicin (DOX)‐induced cardiotoxicity impedes its clinical application, but the mechanisms have not been thoroughly elucidated. Based on circRNA and mRNA expression profiles, we illustrated RNA expression signature changes during DOX‐induced cardiotoxicity; mechanism exploration and biomarkers screening were also conducted. Twelve mice were randomly divided into two groups, induction group was treated with doxorubicin, and the control group was given an equal quantity of saline. After the confirmation of myocardial injury in induction group, the heart tissues from both groups were isolated for RNA high‐throughput sequencing. The expression profiles were compared between the two groups; a total of 295 mRNAs and 11 circRNAs were shown as biased expression in DOX‐induced cardiotoxicity mouse hearts. The dysregulation of three circRNAs were validated by quantitative real‐time PCR: mmu_circ_0015773, mmu_circ_0002106, and mmu_circ_001606. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the differentially expressed RNAs were performed; the results implied that DOX might cause cardiotoxicity by interfering hemoglobin‐based oxygen delivery and DNA‐associated signal pathways. We integrated the differential expressed mRNA and validated circRNAs by constructing a competing endogenous RNA (ceRNA) network, which indicated that the alteration of the three circRNAs could activate apoptosis process of myocardial cells. This study provided novel insight into the mechanisms of DOX induced cardiotoxicity, and potential biomarkers or therapeutic targets were also proposed.
A drop‐in centre for treating mental health problems in children with chronic illness: Outcomes for parents and their relationship with child outcomes
Authors: Bennett Sophie D. , Kerry Eleanor , Fifield Kate , Ching Brian C. F. , Catanzano Matteo , Liang Holan , Heyman Isobel , Coughtrey Anna E. , Sanderson Charlotte , Rojas Natalia , Shafran Roz 
Published: October 2021

AbstractBackgroundChildren with chronic health conditions and their parents are at greater risk of developing emotional and behavioural problems compared to their physically healthy peers. The psychological impact on parents is crucial to understand given the relationship between parental mental health and child emotional and behavioural difficulties. This study was part of a broader research project examining the acceptability, feasibility and impact of a ‘Mental Health and Psychological Wellbeing Drop‐in Centre’ in a paediatric hospital providing access to support and intervention for children and their families. This paper aimed to investigate the impact of the centre on parents (n = 148).MethodsParental anxiety and depression were assessed using the GAD‐7 and PHQ‐9 at baseline and 6‐month post‐baseline. Child mental health was assessed using the parent‐report Strengths and Difficulties Questionnaire (SDQ). If parents had significant mental health needs, a brief intervention/signposting to relevant services was provided.ResultsAt baseline, 48% of parents scored above clinical threshold for anxiety and 41% for depression, and parent reported child SDQ scores were correlated with parental anxiety and parental low mood. Self‐reported parental anxiety and low mood decreased at 6‐months post‐baseline (parental anxiety: mean decrease = 2.29 [1.22–3.36], d = 0.38; parental low mood: mean decrease = 1.81 [0.64–3.00], d = 0.28). There were no significant correlations between change in parent reported child wellbeing and changes in parental low mood and anxiety between baseline and 6‐month post‐baseline.ConclusionsAssessing and providing a brief treatment to address the mental health needs of parents of children with comorbidity may bring important benefits. It is recommended that children's mental health services consider assessment of parental mental health as part of routine care.
Experiences of adolescents and their parents after receiving adolescents’ genomic screening results
Authors: Lillie Natasha , Prows Cynthia A. , McGowan Michelle L. , Blumling Amy A. , Myers Melanie F. 
Published: October 2021

AbstractThere has been considerable debate over whether adolescents should have the opportunity to learn genetic information about adult‐onset disease risk and carrier status without a clinical indication. Adolescents face increasing opportunities to learn more about such genetic risks through the return of secondary findings from clinical genomic testing, direct‐to‐consumer genetic testing, and research opportunities. However, little is known about the perspectives of adolescents who have received genomic screening results. We conducted separate qualitative interviews with 15 adolescents and their parents who enrolled in a research protocol where they decided which genomic screening results to receive for the adolescent for up to 32 conditions informed by 84 genes. The goal of these interviews was to explore the impact of adolescents learning genomic results without a clinical indication for screening. Of the participating dyads, four received positive results for a pathogenic/likely pathogenic (P/LP) variant for an autosomal dominant (AD) condition, five received carrier results for a heterozygous P/LP variant for an autosomal recessive (AR) condition, and six received negative results. An interpretive descriptive qualitative approach was used. Interview transcripts were coded using a guide developed by the study team based on themes that emerged from the interviews. Degree of recall and description of results, actionability, and emotional responses differed according to the types of results received. However, all participants were satisfied with their decision to learn results, and most did not report any lasting psychological harms. Participants adapted to genomic information about themselves, even after learning about unexpected increased risk for future health problems. Our findings support the position that, whenever possible, perspectives and wishes of adolescents should be strongly considered and respected in the decision‐making process regarding genetic testing.
An Australian hospital pharmacy department’s pandemic response plan to coronavirus disease of 2019
Authors: Ziser Kate E.D. , Olding Suzanne H. , Patel Anjali B. , Batger Mellissa R. , Peng Shiqin , Brown Samantha L. , Grieve Fallon C. , Crane Jennifer A. 
Published: October 2021

AbstractAimThis paper provides the main accomplishments of the Royal North Shore Hospital (RNSH) Pharmacy Department’s COVID‐19 Pandemic Response Plan and key recommendations for other departments developing a remote model of care.MethodsThe overall objective was to preserve the active workforce by minimising staff‐to‐staff and staff‐to‐patient contact. The response plan involved splitting the department into teams, implementing a remote ward‐based clinical pharmacy service, staff upskilling and optimising the physical environment.ResultsIn April 2020, 1240 clinical tasks were completed remotely compared with 1254 tasks completed on site. In May 2020, 1700 tasks were completed offsite, compared with 1544 tasks onsite. The percentage of pharmacists rating themselves 5 out of 5 (very confident) in communicating over the phone increased from 34.8% prior to remote service delivery, to 60% after completion of the service. Counselling patients over the phone increased from 17.4% to 40% while providing remote clinical service increased from 26.1% to 80%.DiscussionThe paper provides key recommendations for other sites wanting to implement a remote model of care. There are details of recommendations for communication, adequate skill mix, upskilling, education, training, staff resilience, role expansion and administration.ConclusionThe formation of a team hospital pharmacy department COVID‐19 Pandemic Response Plan has provided assurance that a complete pharmacy service could continue in the event of reduced staffing. Intense, thoughtful, collaborative work was required in a short period of time to design an appropriate physical environment, create a remote working model of care, and to train and educate members of staff.
Effect of typhoon‐induced intertidal‐flat erosion on dominant macrobenthic species (Meretrix meretrix)
Authors: Shi Benwei , Yang Shi Lun , Temmerman Stijn , Bouma Tjeerd , Ysebaert Tom , Wang Sikai , Zhang Yingxin , Wu Jihua , Yang Haifei , Zhang Longhui , Zuo Liqin , Wang Ya Ping 
Published: October 2021

AbstractBenthic animal populations inhabiting intertidal flats provide important ecosystem functions and services that may be disrupted by physical disturbances such as tropical cyclones, which are predicted to increase in frequency and intensity under future climate change. However, the spatial reach at which tropical cyclones impact macrobenthos populations in intertidal flats remains poorly understood. We examined whether a typhoon with a center that remained more than 1400 km away from the study site could trigger severe erosion of intertidal flats and adversely affect macrobenthos populations. We undertook simultaneous measurements of hydrodynamics (waves, currents), morphodynamics (erosion, accretion) and density and biomass of the macrobenthic bivalve Meretrix meretrix during the passage of this typhoon, on an intertidal flat on the Chinese coast. Our results showed that, in spite of the considerable distance from the storm center, the bed shear stress greatly exceeded the critical value for erosion, resulting in rapid erosion of approximately 10 cm and a nearly 50% reduction in both the density and the biomass of the clam species. Our findings suggest that if storms become more frequent and more intense in a future warmer climate, they may increase physical disturbances to intertidal flats and their benthic animal populations, even at great distances from storm centers.
Insomnia in Tourette Syndrome and Chronic Tic Disorder
Authors: Isomura Kayoko , Sidorchuk Anna , Sevilla‐Cermeño Laura , Åkerstedt Torbjörn , Silverberg‐Morse Maria , Larsson Henrik , Mataix‐Cols David , Fernández de la Cruz Lorena 
Published: October 2021

AbstractBackgroundInsomnia is common in Tourette syndrome (TS) and chronic tic disorder (CTD), but precise prevalence estimates are lacking.ObjectiveIn this Swedish register‐based cohort study, we estimated the prevalence of insomnia in TS/CTD and quantified the magnitude of this association, accounting for familial confounders and relevant somatic and psychiatric comorbidities.MethodsOf 10,444,702 individuals living in Sweden during the period from 1997 to 2013, 5877 had a diagnosis of TS/CTD and were compared to unexposed individuals from the general population on the presence of insomnia using logistic regression models.ResultsIndividuals with TS/CTD had a period prevalence of insomnia of 32.16%, compared to 13.70% of the unexposed population. This translated into a 6.7‐fold increased likelihood of insomnia in TS/CTD (odds ratio adjusted [aOR] for sex, birth year, birth country, and somatic disorders = 6.74; 95% confidence interval [CI], 6.37–7.15). A full sibling comparison, designed to adjust for shared familial factors, attenuated the estimates (aOR = 5.41; 95% CI, 4.65–6.30). When individuals with attention‐deficit/hyperactivity disorder (ADHD) and pervasive developmental disorders were excluded, the association was also attenuated, whereas exclusion of other psychiatric comorbidities had minimal impact. Having persistent TS/CTD, comorbid ADHD, and taking ADHD medication greatly increased the likelihood of insomnia.ConclusionsInsomnia is significantly associated with TS/CTD, independently from somatic disorders, familial factors or psychiatric comorbidities, although familial factors, neurodevelopmental comorbidities, and ADHD/ADHD medication may explain part of the association. Insomnia should be routinely assessed and managed in TS/CTD, particularly in chronic patients and in those with comorbid ADHD. Other sleep disorders require further study. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Synthesis and characterization of fluorine functionalized graphene oxide dispersed quinoline‐based polyimide composites having low‐k and UV shielding properties
Authors: Kumar Selvaraj , Arumugham Hariharan , Roy Debmalya , Kannaiyan Dinakaran 
Published: October 2021

AbstractPolyimide nanocomposites having low‐k and UV shielding properties have been developed using fluorine functionalized graphene oxide and bis(quinoline amine) based polyimide. The polyimide was synthesized using bis(quinoline amine) and pyromellitic dianhydride at appropriate experimental conditions, and its molecular structure was confirmed through various spectral analysis such as FTIR and NMR. The polyimide (PI) composites were prepared using bis(quinoline amine), pyromellitic dianhydride, and separately filled with 1, 5, 10 wt% of fluorinated graphene oxide (FGO) through in situ polymerization. The polymer composites were characterized using thermo gravimetric analysis (TGA), X‐ray powder diffraction (XRD), and scanning electron microscopy (SEM). In addition, the water contact angle, dielectric behavior, and UV–Vis shielding behavior of FGO/PI composites were evaluated. The value of the water contact angle of the polyimide was increased with increment of FGO in the polyimide matrix. The highest water contact angle of polyimide composites observed 108° was obtained for 15 wt% FGO reinforced polyimide composite. The value of the dielectric constant for neat, 1, 5, and 15 wt% FGO reinforced polyimide composites was obtained as 4.5, 3.7, 2.6, and 2.0, respectively. It is also observed from by UV–Vis spectroscopy analysis that the FGO reinforced polyimide composites have good UV shielding behavior.
de Sitter Space as a Glauber‐Sudarshan State: II
Authors: Bernardo Heliudson , Brahma Suddhasattwa , Dasgupta Keshav , Faruk Mir‐Mehedi , Tatar Radu 
Published: October 2021

AbstractWe provide further evidence to support the fact that a four‐dimensional effective field theory description with de Sitter isometries in IIB string theory, overcoming the no‐go and the swampland criteria, can only exist if de Sitter space is realized as a Glauber‐Sudarshan state. We show here that this result is independent of the choice of de Sitter slicings. The Glauber‐Sudarshan state, constructed by shifting the interacting vacuum in the M‐theory uplift of the scenario, differs from a standard coherent state in QFT in the sense that the shape and size of the state changes with respect to time, implying changes in the graviton and the flux quanta. Despite this, the expectation values of the graviton and flux operators in such a state reproduce the exact de Sitter background, as long as we are within the temporal bound set by the onset of the strong coupling in the dual type IIA side, and satisfy the corresponding Schwinger‐Dyson's equations in the presence of hierarchically controlled perturbative and non‐perturbative quantum corrections.Additionally, we provide a detailed study of the fluxes supporting the Glauber‐Sudarshan state in the M‐theory uplift of the IIB scenario. We show explicitly how the Bianchi identities, anomaly cancellation and flux quantization conditions, along‐with the constraints from the Schwinger‐Dyson's equations, conspire together to provide the necessary temporal dependences to support such a state in full M‐theory. We also discuss how our analysis points towards a surprising connection to the four‐dimensional null energy condition, for a Friedman‐Lemaitre‐Robertson‐Walker state in the IIB side, as a consistency condition for the existence of an effective field theory description in M‐theory.
Response‐adaptive treatment allocation for clinical studies with recurrent event and terminal event data
Authors: Su Pei‐Fang 
Published: October 2021

AbstractIn long‐term clinical studies, recurrent event data are frequently collected to contrast the efficacy of two different treatments. However, the recurrent event process can be stopped by a terminal event, such as death. For analyzing recurrent event and terminal event data, joint frailty modeling has recently received considerable attention because it makes it possible to study the joint evolution over time of both recurrent and terminal event processes and gives consistent and efficient parameters. For a two‐arm clinical trial design based on these data sets, there has been limited research on investigating the balanced design, let alone adaptive treatment allocation. Although equal sample size allocation obtained for both treatments is intuitively first adopted in a trial design, if one treatment is expected to be superior, it may be desirable to allocate more subjects to the effective treatment. In this article, we calculate the required sample size based on restricted randomization and then propose a target response‐adaptive randomization procedure for recurrent and terminal event outcomes based on the joint frailty model. A randomization procedure, the doubly adaptive biased coin design that targets some optimal allocations, is implemented. The proposed adaptive treatment allocation schemes have been shown to be capable of reducing the number of trial participants who receive inferior treatment while simultaneously reaching an optimal target, as well as retaining a comparable test power as compared to a restricted randomization design. Finally, two clinical studies, the COAPT trial and the A‐HeFT trial, are used to illustrate the advantages of adopting the proposed procedure.
An Insight into the Biological Properties of Imidazole‐Based Schiff Bases: A Review
Authors: Gopalakrishnan Anjali K. , Angamaly Shanty A. , Velayudhan Mohanan P. 
Published: October 2021

AbstractImidazole is an azole heterocycle containing two non‐adjacent nitrogen atoms added greatly to natural products and synthetic compounds. The planar ring system associated with electron‐rich nitrogen donors are essential for the greater affinity of imidazole derivatives to bind with various bio receptors and enzymes via weak interactions. It improves the pharmacokinetic properties of the pilot molecules consequently utilized as a solution for aqueous solubility, bioavailability, and toxicity parameters since it is a polar compound. An organic molecule with imidazole derivatives has acquired a sustainable place in medical and clinical fields. The consolidation of the imidazole unit is a significant synthetic technique in drug development. The imidazole‐based Schiff bases with enormous therapeutic properties has encouraged the scientists to focus on recently initiated novel chemotherapeutic agents such as anticancer, antimicrobial, antioxidant, antiviral, antileishmanial, etc. Imidazole drugs have expanded the degree of curing different dispositions in clinical medications. Herein, we have reported the structural feature of imidazole, design, synthesis of imidazole derivatives, and its significance. This review aims to describe the reported materials of imidazole‐based Schiff bases and their derivatives which offer fruitful scope in the field of medicinal chemistry.
From mass to motion: Conceptualizing and measuring the dynamics of industry clusters
Authors: Kim Min Jung , Shaver J. Myles , Funk Russell J. 
Published: October 2021

AbstractResearch SummaryAn extensive body of research examines concentration levels (i.e., “mass”) of industry clusters; however, little attention is paid to their dynamics (i.e., “motion”). Understanding cluster dynamics is important because how clusters change over time may have implications for firm strategies and outcomes that are not attributable to cluster mass alone. To advance scholarship, we derive a theoretically grounded measure of cluster motion. Applying this measure to data on establishments in the U.S. computer and semiconductor industries, we document the dynamic nature of clusters both within and across regions. We demonstrate that our measure of cluster motion is distinct from cluster mass. Furthermore, we document that regions rarely follow stylized descriptions of cluster life cycles, which underscores the importance of measuring and investigating cluster dynamics.Managerial SummaryIndustry clusters have been considered important for firm strategy due to their influence over organizational processes and outcomes. Therefore, many firms attend closely to how clusters change over time. However, strategy researchers have devoted relatively little attention to cluster dynamics and their implications for firms. In this study, we develop a framework for understanding cluster dynamics, including an empirical technique. We suggest that improved understanding of cluster dynamics may be useful for helping firms make better location decisions and react more appropriately to changes in clusters within which they have an established presence.
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
Authors: Goessens Laurent , Colombel Jean‐Frédéric , Outtier An , Ferrante Marc , Sabino Joao , Judge Ciaran , Saeidi Reza , Rabbitt Louise , Armuzzi Alessandro , Domenech Eugeni , Michalopoulos George , Cremer Anneline , García‐Alonso Francisco Javier , Molnar Tamas , Karmiris Konstantinos , Gecse Krisztina , Van Oostrom Joep , Löwenberg Mark , Farkas Klaudia , Atreya Raja , Ribaldone Davide Giuseppe , Selinger Christian , Hoentjen Frank , Bihin Benoit , Sebastian Shaji ,   European COMBIO study group, Rahier Jean‐François 
Published: October 2021

AbstractBackground and aimsFew data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series.MethodsCombination therapy was defined as the concomitant use of two biologics or one biologic with a small molecule. Patient demographics, disease characteristics and types of combinations were recorded. Safety was evaluated according to the occurrence of serious infection, opportunistic infection, hospitalisation, life‐threatening event, worsening of IBD or immune‐mediated inflammatory diseases (IMID), cancer and death. Efficacy was evaluated as the physician global assessment of the combination and comparison of clinical/endoscopic scores of IBD/IMID activity prior and during combination.ResultsA total of 104 combinations were collected in 98 patients. Concomitant IMID were present in 41 patients. Reasons for starting combination therapy were active IBD (67%), active IMID or extra‐intestinal manifestations (EIM) (22%), both (10%) and unclassified in 1. Median duration of combination was 8 months (interquartile range 5–16). During 122 patient‐years of follow‐up, 42 significant adverse events were observed, mostly related to uncontrolled IBD. There were 10 significant infections, 1 skin cancer and no death. IBD disease activity was clinically improved in 70% and IMID/EIM activity in 81% of the patients. Overall, combination was continued in 55% of the patients.ConclusionsCombination of biologics and small molecules in patients with IBD and IMID/EIM seems to be a promising therapeutic strategy but is also associated with a risk of opportunistic infections or infections leading to hospitalisation in 10%.